Lupin’s Big Move: Subsidiary Shake-Up to Turbocharge OTC and API Ambitions

Lupin Limited announced substantial progress in two major business restructuring initiatives, expected to be completed by June 30, 2025. The company's Board has sanctioned an amendment in its previous slump sale transaction for the sale of its Over-the-Counter (OTC) Consumer Healthcare Business. The amendment involves the inclusion of one additional brand in the transfer, increasing the value and strategic scope of the deal. The OTC business, with an approximate net worth of ₹1,680 million as of March 31, 2024, will be demerged on a going concern basis to the newly formed, wholly owned subsidiary, LupinLife Consumer Healthcare Limited (LCHL). The Business Transfer Agreement (BTA) between Lupin and LCHL is likely to be signed by June 30, 2025, with the transaction consideration pegged in the range of ₹8,000 million to ₹9,000 million, subject to adjustment.

 

At the same time, Lupin is also completing the transfer of its API R&D Division to Lupin Manufacturing Solutions Limited (LMSL), another wholly owned subsidiary, on a slump sale basis. Both transactions are structured to sharpen Lupin's concentration on its core prescription business while unlocking value and growth potential in the fast-growing OTC and API segments. These actions reaffirm Lupin's dedication to operational agility, strategic clarity, and increased stakeholder value.

 

Sources: Lupin Board Meeting Outcome, Business Standard, The Hindu BusinessLine